

Phase 2b, double-blind, randomised, placebo-controlled trial. Patients with moderate to severe ulcerative colitis were randomized to daily oral ABX464 (100mg, 50mg, 25mg) or matched placebo.


Primary endpoints: Change from baseline in modified Mayo score (MMS) at week 8.

Results:

- At week 8 median change from baseline in MMS was significantly superior in all ABX464 doses (-2.9 in 100mg; -3.2 in 50mg; -3.1 in 25mg vs -1.9 placebo, $p=0.0039$, $p=0.0003$, $p=0.0010$ respectively against placebo).
- Most frequent adverse event was headache.

Conclusion:

All doses of ABX464 significantly improved moderate to severe, active ulcerative colitis compared with placebo, as measured by changes in MMS from baseline to week 8.



*Obefazimod is a small molecule that selectively upregulates miR-124 in immune cells.

